Victoria Villaflor, MD joins UCI Health to share key insights from the 2025 ASCO Annual Meeting
Victoria Villaflor, MD, a recent addition to the UCI Health Chao Family Comprehensive Cancer Center faculty, highlights pivotal findings from ASCO 2025.
Clinical Scorecard: Insights from the 2025 ASCO Annual Meeting on Head and Neck Oncology
At a Glance
Category Detail
Condition Head and Neck Squamous Cell Carcinoma Key Mechanisms Adjuvant immunotherapy with nivolumab and other agents Target Population Patients with high-risk, resected head and neck squamous cell carcinoma Care Setting Oncology clinics and comprehensive cancer centers
Key Highlights
NIVOPOSTOP trial showed 10% improvement in recurrence-free survival with nivolumab. Emerging evidence suggests practice-changing therapies in postoperative settings. Positive outcomes observed in cutaneous squamous cell carcinoma with immunotherapy. Keynote 689 trial indicated improvement in event-free survival with pembrolizumab. Cemiplimab demonstrated significant event-free survival improvement in postoperative settings. Guideline-Based Recommendations
Diagnosis
Evaluate high-risk patients for potential adjuvant immunotherapy. Management
Consider nivolumab as part of the postoperative treatment regimen. Monitoring & Follow-up
Monitor for recurrence and treatment response in patients receiving immunotherapy. Risks
Assess potential adverse effects of immunotherapy in high-risk populations. Patient & Prescribing Data
High-risk patients post-surgery for head and neck squamous cell carcinoma.
Immunotherapy may significantly improve outcomes in this population.
Clinical Best Practices
Incorporate immunotherapy into treatment plans for eligible patients. Stay updated on emerging clinical trial results for head and neck oncology. References
